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Abstract
Recently, dynamic risk stratiﬁcation has been found to be more valuable than static anatomic staging system in nonmedullary thyroid
cancer and this strategy has also been accepted in medullary thyroid cancer (MTC). The present study was designed to compare the
clinical usefulness of response to initial therapy stratiﬁcation with a traditional anatomic staging system.
From August 1982 to December 2012, a total of 144MTC patients underwent thyroidectomy in Yonsei University Hospital. Among
them, 117 (82.2%) patients with complete clinical data and sustained follow-up were enrolled in this study. Clinicopathological
features and surgical outcomes were analyzed by retrospective medical chart review. Mean follow-up duration was 85.78±62.51
months.
In this study, mean tumor size was 1.94±1.40cm and 22 (18.9%) patients had hereditary MTC; 95 (81.1%) patients had sporadic
MTC. Stage I patients had highest probability of excellent response to initial therapy (92.1%). Stage IV patients had highest probability
of biochemical and structural incomplete response to initial therapy (57.5% and 30.3%) and lowest probability of excellent response
to initial therapy (12.1%). Both response to initial therapy stratiﬁcation and TNM staging system offered useful prognostic information
in this study. The TNM staging system provided risk stratiﬁcation pertaining to disease-free survival (DFS), disease-speciﬁc survival
(DSS), and the probability of having no evidence of disease at ﬁnal outcome, but did not provide risk stratiﬁcation pertaining to the
probability of having biochemical persistent/recurrence disease at ﬁnal outcome. However, response to initial therapy stratiﬁcation
provided risk stratiﬁcation pertaining to not only DFS, DSS, and the probability of having no evidence of disease at ﬁnal outcome but
also the probability of having biochemical persistent/recurrence disease at ﬁnal outcome.
In this study, we demonstrated that dynamic risk stratiﬁcation with adjusted response to initial therapy system can offer more useful
prognostic information than anatomic staging system in MTC.
Abbreviations: AJCC = American Joint Committee on Cancer, ATA = American Thyroid Association, CEA = carcinoembryonic
antigen, CI = conﬁdence interval, DFS = disease-free survival, DRS = Dynamic Risk Stratiﬁcation, DSS = disease-speciﬁc survival,
IAUC = Integrated Areas Under the Curves, LN = lymph node, MTC =medullary thyroid carcinoma, NED = no evidence of disease,
NMTC = nonmedullary thyroid carcinoma, PVE = proportion of variance explained, ROC = receiver operating characteristic, TNM =
tumor-node-metastasis, US = ultrasonography.
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Medullary thyroid carcinoma (MTC) is a rare cancer that
accounts for 3% to 10% of all thyroid cancers.[1] MTC has aEditor: Gaurav Malhotra.
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1more aggressive biological behavior than papillary thyroid
carcinoma. Metastasis to regional lymph nodes (LNs) in the
central compartment is reported in 50% to 81% of patients and
to the lateral compartments in 34% to 81%.[2]MTC accounts for
8% to 13% of all thyroid cancer related mortalities because of
distant metastasis.[3] For these reasons, recognizing prognostic
factors is important. Age, male sex, extrathyroidal invasion,
cervical LN metastasis, distant metastasis, sporadic or hereditary
disease, delay in diagnosis, and incomplete surgical treatment are
known to be prognostic factors for MTC.[3]
The tumor-node-metastasis (TNM) staging system of the
American Joint Committee on Cancer (AJCC) is based on the
anatomical and structural extent of thyroid cancer and has a good
correlation with disease-related mortality. However, the TNM
staging system has static risk estimates that do not change over time
as clinical data accumulate. Besides, the TNM staging system does
not predict the risk of persistent or recurrent disease because it does
not include important prognostic factors such as age and
biochemical markers. Dynamic risk stratiﬁcation (DRS) has been
found to be more valuable than the static, anatomical TNM staging
system for nonmedullary thyroid cancer (NMTC), and risk-adapted
management stratiﬁed by response to initial therapy has been
[4]
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Biochemical markers such as serum calcitonin and carcinoem-
bryonic antigen (CEA) are important forMTCprognosis. The 2015
revised American Thyroid Association (ATA) guidelines recom-
mend that clinicians should consider TNM classiﬁcation and
postoperative serum calcitonin level when predicting outcomes and
planning long-term follow-up for patients treated by thyroidectomy
for MTC.[5] Several studies found that DRS predicts risk of
biochemical and structural persistent or recurrent disease as well as
disease-related mortality from MTC.[3,6]
In this study, we evaluated and compared the clinical
usefulness of stratiﬁcation by response to initial therapy with a
traditional anatomical TNM staging system for MTC treated at
Yonsei University Health System.2. Materials and methods
2.1. Study population
The medical records of patients diagnosed with MTC from
August 1982 to December 2012 were reviewed retrospectively. A
total of 144 patients with MTC underwent thyroidectomy in the
Yonsei University Heath System. Among these patients, 27 were
not followed continuously and had incomplete medical records.
Thus, 117 patients were reviewed in this study. All patients had
conventional open operations. Mean follow-up duration was
85.78±62.51 months. This study was approved by the local
institutional review board.2.2. Outcome assessment
To evaluate clinicopathological features, clinical and pathologi-
cal parameters of multi-centricity, bi-laterality, extrathyroidal
extension, central LN metastasis, lateral neck LN metastasis,
TNM staging, and response to initial therapy were analyzed. We
used 7th edition AJCC TNM staging system. In 2016, 8th edition
AJCC TNM staging system was published. However, there is no
signiﬁcant change in 8th edition compared with 7th edition.
To evaluate surgical outcomes, all patients underwent regular
follow-up ultrasonography (US) in ﬁrst 6 to 12 months after
initial surgery, followed by annual examination after 3 years.
Serum calcitonin and CEA were also checked in the ﬁrst 6 to
12 months after initial surgery, followed by annual examination
after 3 years. Patients with evidence of recurrence or distant
metastasis were examined using other imaging modalities, such
as neck computed tomography (CT) and/or positron emission
tomography-CT (PET-CT). Regional neck node and remaining
thyroid recurrence were conﬁrmed by US-guided ﬁne needle
aspiration biopsy.
We used 3 clinical results for response to initial therapy:
excellent, biochemically incomplete, and structurally incomplete
response. We used 5 clinical results for ﬁnal outcomes: no
evidence of disease (NED), biochemically persistent, structurally
persistent, biochemically recurrent, and structurally recurrent.
Response to initial therapy was evaluated during the ﬁrst 6 to 12
months after initial operation.
Serum calcitonin was measured using immunoradiometric
assays (CT-USA-IRMA; Biosource, Nivelles, Belgium) from 1994
to 2009, when these tests were replaced with chemiluminescence
DPC immunoassays (Immulite 2000; Siemens, Gwynedd, UK).
Normal range was 0 to 10pg/mL. Serum CEA measurement was
by immunoassays (Unicel DxI 800; Beckman Coulter, Pasadena,
USA). Normal range was 0 to 5ng/mL.2Disease-speciﬁc survival (DSS) was deﬁned as the time from
date of initial surgery to the date of death from thyroid cancer or
last follow-up. Disease-free survival (DFS) was deﬁned as the time
from date of initial surgery to the date of detection of ﬁrst
recurrence. These factors were analyzed to evaluate prognostic
results.2.3. Deﬁnition of surgical outcomes
For response to initial therapy, excellent response was deﬁned as
no structural evidence of disease and normalized serum calcitonin
and CEA levels after initial operation. Biochemically incomplete
response was deﬁned as no structural evidence of disease after
initial operation, but serum calcitonin and CEA levels higher than
normal range. Structurally incomplete response was deﬁned as
structural evidence of disease after initial operation.
We deﬁned NED as undetectable calcitonin and CEA with no
structural evidence of disease.[4] Biochemically persistent disease
was deﬁned as detectable calcitonin and CEA with no structural
evidence of disease. Structurally persistent disease was deﬁned as
structural evidence of disease regardless of biochemical
markers.[4] Patients with newly developed biochemical or
structural evidence of disease after NED were classiﬁed as
having biochemically or structurally recurrent disease.[4]2.4. Statistical analysis
Weused SPSS software version 20.0 (IBM Inc., Chicago, IL) and R
package version 3.1.3 for all statistical analysis. Rates and
percentages were calculated for categorical data andmedians were
calculated for continuous data. DSS andDFSwere estimated using
Kaplan–Meier survival curves according to the AJCC TNM
staging system and DRS and compared by log-rank test with SPSS
software. Survival estimates and 95% conﬁdence intervals (CIs)
were recorded for 5, 10, 15, 20, and25years of follow-up.Relative
importance for predicting the likelihood of NED between TNM
staging and DRS was conﬁrmed by calculating the proportion of
variance explained (PVE) with R package. PVE was calculated
using themaximum likelihood ratio (G2) of the Coxmodel (PVE=
1- exp [-G2/n]). Higher PVE values suggested more accurate
prediction ofNED.[7,8]Wealso evaluated the discriminative ability
of TNM staging and DRS using integrated areas under the curves
(IAUCs) with R package. IAUCs were compared using results of
time-dependent receiver operating characteristic (ROC) curves at
selected time-points. The statistical test for IAUCswas aWilcoxon
rank sum test fordependent samples.Higher IAUCsuggestedmore
accurate risk stratiﬁcation. P values less than .05 were considered
statistically signiﬁcant.3. Results
3.1. Clinicopathological characteristics of patients with
MTC
Patient clinicopathological characteristics for MTC are summa-
rized in Table 1. Of patients with MTC, a higher proportion was
female (68.4% vs 31.6%). Mean tumor size was 1.94±1.40cm
andmean age was 47.98±15.11 years. HereditaryMTCwas seen
in 22 patients (18.9%). Frequencies were multi-centricity 30.7%,
bi-laterality 5.2%, extrathyroidal invasion 35.0%, central LN
metastasis 34.1%, and lateral neck LN metastasis 25.6%. Of a
total of 117 patients, 115 (98.2%) underwent bilateral total
thyroidectomy with 38 (32.4%) undergoing bilateral total
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Stage I 51 (43.5%)
Stage II 21 (17.9%)
Stage III 12 (10.2%)
Stage IVa 23 (19.6%)
Stage IVb 3 (2.5%)
Stage IVc 7 (6.0%)
Response to initial therapy
Excellent 73 (62.3%)
Biochemically incomplete 30 (25.6%)
Structurally incomplete 14 (11.9%)
Final outcome
Death 22 (18.8%)
No evidence of Ds (NED) 66 (56.4%)
Biochemically persistent 21 (17.9%)
Structurally persistent 1 (0.85%)
Biochemically recurrent 3 (2.56%)
Structurally recurrent 4 (3.41%)
TNM= tumor-node-metastasis.
Table 1
Clinicopathological characteristics of patients with medullary
thyroid carcinoma (1).
Variable Patients (N=117)
Age, y, Mean±SD 47.98±15.11
Male/female ratio 37/80 (31.6%/68.4%)
T size, cm, mean±SD 1.94±1.40
Tumor type
Hereditary MTC 22 (18.9%)

















Bilateral total thyroidectomy 115 (98.2%)
Less than total thyroidectomy 2 (1.8%)
Follow-up duration (months) mean±SD 85.78±62.51
MTC=medullary thyroid carcinoma, SD= standard error.
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with therapeutic purpose and16with prophylactic purpose and16
(13.6%) undergoing bilateral total thyroidectomy with bilateral
modiﬁed radical neck dissection; 5 with therapeutic purpose and
11 with prophylactic purpose. Although there was no clue of
lateral neck LN metastasis in preoperative image, we performed
prophylactic lateral neck dissections in patients with MTC in our
institution until 2008. Since 2008, lateral neck dissections in
patients with MTC have been performed only for therapeutic
purpose. In addition, 2 (1.8%) patients underwent less than total
thyroidectomy. One patient had undergone thyroid lobectomy for
benign nodules previously, followed by completion total thyroid-
ectomy to treatMTCa fewyears later.Theotherpatientperformed
thyroid lobectomy for papillary thyroid micro-carcinoma and
concurrently pathologically proven occult MTC. We considered
completion total thyroidectomy for this patient, but eventually we
planned to do no additional surgery with the consent of patient.
For TNM staging of the MTC patients, 7 (6.0%) had distant
metastasis. Among 7 patients with distant metastasis, 2 had lung
metastasis and 5 had multiple metastases in lung and bone. All
patients died because of disease progression. Staging was stage I
43.5%; stage II, 17.9%; stage III, 10.2%; stage IVa, 19.6%; stage
IVb, 2.5%; and stage IVc, 6.0%. Of 117 patients, 73 (62.3%)
were classiﬁed in the excellent group, 30 (25.6%) were in the
biochemically incomplete response group, and 14 (11.9%) were
in the structurally incomplete response group. In ﬁnal outcomes,
66 (56.4%) patients were classiﬁed in the NED group, 21
(17.9%) in the biochemically persistent group, and 1 (0.85%) in
the structurally persistent group; 3 (2.56%) patients were in the
biochemically recurrent group and 4 (3.41%) in the structurally
recurrent group, with 22 (18.8%) patients who died, with 15
disease-speciﬁc deaths (Table 2).33.2. Clinical outcomes according to the AJCC TNM
staging system
The AJCC TNM staging system predicted the clinical outcomes
of MTC patients. Final outcomes according to the staging system
are summarized in Table 3. Of the 15 patients who died from
their disease, 12 (80%) had stage IV disease. Classiﬁed with NED
was 90.1% of stage I patients, 41.6% of stage III patients, and
6.1% of stage IV patients. In addition, 3 (5.8%) patients with
stage I and 2 (9.5%) patients with stage II disease were classiﬁed
in biochemically persistent. All patients classiﬁed with structural
recurrence were stage IV. Cumulative survivals of MTC patients
according to the AJCC TNM staging system showed signiﬁcant
differences in survival. We excluded patients with biochemically/
structurally persistent disease in DFS analysis. With higher AJCC
TNM staging grades, DFS (P< .001, Fig. 1A) and DSS (P< .001,
Fig. 1B) were lower.
3.3. Clinical outcomes according to response to initial
therapy
A DRS system based on response to initial therapy predicted
clinical outcomes of MTC patients. Final outcomes according to
the DRS system are summarized in Table 4. MTC patients with
an excellent response had the highest likelihood of NED (89%).
One patient with a biochemically incomplete response was
classiﬁed with NED and no patients with structurally incomplete
Table 3
Clinical outcomes according to the AJCC TNM Staging System.
TNM staging
Final outcome Stage I (N=49) Stage II (N=18) Stage III (N=11) Stage IV (N=32)
Death (N=15) 0 2 (13.3%) 1 (6.6%) 12 (80%)
No evidence of Ds (NED) (N=66) 46 (69.6%) 13 (19.6%) 5 (7.5%) 2 (3%)
Biochemically persistent (N=21) 3 (14.2%) 2 (9.5%) 4 (19%) 12 (57.1%)
Structurally persistent (N=1) 0 0 0 1 (100%)
Biochemically recurrent (N=3) 0 1 (33.3%) 1 (33.3%) 1 (33.3%)
Structurally recurrent (N=4) 0 0 0 4 (100%)
AJCC=American Joint Committee on Cancer, TNM= tumor-node-metastasis.
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biochemically incomplete response, 4 (13%) had structurally
recurrent disease; 2 patients had lateral neck recurrences and we
considered surgical treatments for these patients; 1 patient had 1
lateral neck recurrence and we performed ethanol injection for
this patient and there was no progression of disease until now;
1 patient had multiple recurrences in lung and bone and this
patient had chemotherapy and 19 (63%) had biochemically
persistent disease. In the excellent response group, 3 (4.1%)
patients had biochemically recurrent disease and none had
structurally recurrent disease at the end of follow-up. No patients
in the excellent response group died from MTC. Two (14.2%)
patients in the structurally incomplete response group had
biochemically persistent disease after reoperation. Analysis of
cumulative survival of MTC patients according to the DRS
system showed signiﬁcant differences in survival. We excluded
patients with biochemically/structurally persistent disease in DFS
analysis. With higher DRS grades, DFS (P< .001, Fig. 2A) and
DSS (P< .001, Fig. 2B) were lower.
3.4. Correlation between AJCC TNM staging and DRS
The AJCC TNM staging system demonstrated good correlation
with the DRS based on response to the initial therapy (Table 5).
Most patients with stage I (92.1%) or stage II (76.1%) disease
were also categorized in the excellent response group within 1
year after initial therapy with 50% of patients with stage III and
12% with stage IV MTC categorized in the excellent responseFigure 1. (A) DFS stratiﬁed by TNM staging system. The 5-year DFS rates were 100
disease. The ten-year DFS rates were 98.2% with stage I, 85.7% with stage II, 71
staging system. The 5-year DSS rates were 100% with stage I, 90.5% with stage II
were 100% with stage I, 90.5% with stage II, 90.3% with stage III, and 65.5% w
4group. The biochemically incomplete response group was
classiﬁed as 5% with stage I, 9% with stage II, 50% with stage
III, and 57% with stage I IV disease.3.5. Predictive ability with AJCC TNM staging and DRS
To evaluate the relative importance of predicting the likelihood of
NED, PVEs were determined for both the TNM staging and the
DRS system based on response to initial therapy. PVEwas 57.7%
for the DRS system, which was higher than the TNM staging
system (25.8%). We also calculated IAUCs to evaluate
discrimination of the TNM staging and DRS systems based on
response to the initial therapy. IAUC was 0.661 (95% CI 0.613–
0.701) for the DRS system, which was higher than the TNM
staging system (0.615; 95% CI 0.583–0.671) (P= .0012, Fig. 3).
4. Discussion
A DRS system based on response to initial therapy gave more
useful clinical prognostic information and was more valuable
than the static, anatomical TNM staging system for NMTC.
Recently, DRS has been accepted for MTC.[3,4,6,9,10] We
evaluated the clinical importance of DRS for MTC patients at
our single institution. Both the DRS and TNM staging systems
predicted clinical outcomes of MTC patients. The DRS system
demonstrated a good correlation with the TNM staging system.
However, the DRS system was a more valuable predictor of NED
than the TNM system because of its higher PVE values (57.7% vs%with stage I, 90%with stage II, 90.5%with stage III, and 63.4%with stage IV
.3% with stage III, and 20.5% with stage IV disease. (B) DSS stratiﬁed by TNM
, 90.3% with stage III, and 72.5% with stage IV disease. The 10-year DSS rates
ith stage IV disease.
Table 4
Clinical outcomes according to response to initial therapy.
Response to the initial therapy
Final outcome Excellent (N=68) Biochemically incomplete (N=28) Structurally incomplete (N=14)
Death (N=15) 0 4 (26.6%) 11 (73.3%)
No evidence of Ds (NED) (N=66) 65 (98.4%) 1 (1.5%) 0
Biochemically persistent (N=21) 0 19 (90.4%) 2 (9.5%)
Structurally persistent (N=1) 0 0 1 (100%)
Biochemically recurrent (N=3) 3 (100%) 0 0
Structurally recurrent (N=4) 0 4 (100%) 0
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predictive system than the TNM system because of its higher
IAUC values (0.661; 95% CI 0.613–0.701 vs 0.615; 95% CI
0.583–0.671, respectively).
Although clinical data for MTC patients change after initial
therapy, the TNM staging system does not change over
time.[3,4,6,10] In our study, 50% of patients with stage III disease
and 12% of patients with stage IV MTC were categorized in the
excellent response groupafter initial therapy (Table5).Thisﬁnding
demonstrated that MTC patients with stage III and IV disease at
initial diagnosis could have an excellent response to initial therapy
and good clinical outcomes. In the groupwith excellent response to
initial therapy, no patients died from their disease.
TheTNMstaging system is an independent prognostic factor for
DSS.[11,12] According to a previous study, 10-yearDSS is 100%for
stage I and II disease, 66%for stage III, and 48% for stage IV.[12] In
our study, DSS according to TNM staging was signiﬁcantly
different (P< .001, Fig. 1B). Similarly, DSS according to the DRS
system was signiﬁcantly different (P< .001, Fig. 2B). However,
mortality rates according to TNM staging were 9.5% for stage II
disease, 8.3% for stage III, and 36.3% for stage IV (Table 3).
Mortality rates according to the DRS system were 13.3% in the
biochemically incomplete response group and 78.5% in the
structurally incomplete response group (Table 4). These ﬁndings
suggested that the DRS system might be more valuable for
predicting mortality than TNM staging. Also, we should always
consider the possibility of high mortality rates with biochemically
incomplete response after initial therapy in MTC patients.Figure 2. (A) DFS stratiﬁed by response to therapy. The 5-year DFS rates were 10
with structurally incomplete group. The 10-year DFS rates were 100% with excelle
incomplete group. (B) DSS stratiﬁed by response to therapy. The 5-year DSS rates
and 20% with structurally incomplete group. The 10-year DSS rates were 100% w
structurally incomplete group.
5Postoperative serum calcitonin levels are thought to be
important prognostic factors in MTC patients.[5,13–15] However,
the TNM staging system does not include postoperative serum
calcitonin levels. A previous study found that 35% of MTC
patients with normal postoperative serum calcitonin showed a 3-
year DFS of 94% and 5-year DFS of 90%.[15] In our study, of 30
patients with biochemically incomplete response, 4 (13.3%)
patients (stage II, 2; stage III, 1; stage IV, 1) died from their disease
and 4 (13.3%) had structurally recurrent disease (Tables 3 and
4). This ﬁnding suggested that patients with biochemically
incomplete response should receive a careful and strict follow-up
for structural evidence of disease.
Previous studies reported that the TNM staging system does
not adequately predict risk of recurrent disease in MTC
patients.[4,6] In contrast to previous studies, our study showed
that DFS according to both the TNM staging and DRS system
were signiﬁcantly different (P< .001, Figs. 1A and 2A). However,
with the DRS system, all but 3 patients in the excellent response
group reached NED. This ﬁnding suggested that the DRS system
might be more valuable for predicting recurrent disease than
TNM staging. In the excellent response group, 3 patients had
biochemically recurrent disease. On the basis of this ﬁnding, we
might consider the possibility of recurrence for MTC patients
with an excellent response after initial therapy rather than for
NMTC patients.
In our study, 65 (89%) patients in the excellent response group
reached NED and 3 (4.1%) had biochemically recurrent disease.
However, 11 (78.5%) patients died from their disease and no0% with excellent group, 80.3% with biochemically incomplete group and 0%
nt group, 42.3% with biochemically incomplete group, and 0% with structurally
were 100% with excellent group, 95.1% with biochemically incomplete group,
ith excellent group, 90.3% with biochemically incomplete group, and 20% with
Table 5
Correlation between AJCC TNM Staging System and DRS.
Stage I (N=51) Stage II (N=21) Stage III (N=12) Stage IV (N=33)
Excellent response (N=73) 47 (64.3%) 16 (21.9%) 6 (8.2%) 4 (5.4%)
Biochemically incomplete response (N=30) 3 (10%) 2 (6.6%) 6 (20%) 19 (63.3%)
Structurally incomplete response (N=14) 1 (7.1%) 3 (21.4%) 0 10 (71.4%)
AJCC=American Joint Committee on Cancer, DRS=dynamic risk stratiﬁcation, TNM= tumor-node-metastasis.
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group. One patient in the structurally incomplete response group
still had structurally persistent disease at ﬁnal outcomes (Table 4).
Kebebew et al[16] reported that reoperation for MTC patients
with grossly residual cancer rarely reach biochemical cure, even if
surgery limits progression of disease in some patients. In our data,
2 (14.2%) patients in the structurally incomplete response group
had biochemically persistent disease as a result of reoperation,
consistent with a previous study. These ﬁndings demonstrated
that complete surgical resection (R0 resection) at initial therapy
was important for survival of MTC patients.
In our study, only 1 patient with biochemically incomplete
response reached NED. This patient did not have increased
calcitonin levels, but increased CEA levels at the ﬁrst evaluation
after initial treatment. This patient was classiﬁed in the
biochemically incomplete response group. He eventually reached
NED at ﬁnal outcome with a normalized CEA level. We propose
that the increased CEA resulted from other causes such as
smoking or infection, in this case.
This study had limitations with the retrospective study and
small numbers of patients. Preoperative serum calcitonin and
germline RET status were not considered, but we plan to conduct
further studies on the associations between prognosis of MTC,
gene mutation status, and calcitonin doubling time. Selection bias
was the main limitation of this study because our single
institution performed both initial therapy and follow-up.Figure 3. Time-dependent IAUC. IAUC was 0.661 (95% CI 0.613–0.701) for
the DRS system based on response to the initial therapy, which was higher
than the TNM staging system (0.615; 95% CI 0.583–0.671).
6In conclusion, we demonstrated that DRS based on response to
the initial therapy offered more useful prognostic information
than an anatomical staging system for MTC in this study.References
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